223 related articles for article (PubMed ID: 21606419)
1. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Tzelepi V; Efstathiou E; Wen S; Troncoso P; Karlou M; Pettaway CA; Pisters LL; Hoang A; Logothetis CJ; Pagliaro LC
J Clin Oncol; 2011 Jun; 29(18):2574-81. PubMed ID: 21606419
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
[TBL] [Abstract][Full Text] [Related]
4. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Garzotto M; Higano CS; O'Brien C; Rademacher BL; Janeba N; Fazli L; Lange PH; Lieberman S; Beer TM
Cancer; 2010 Apr; 116(7):1699-708. PubMed ID: 20143429
[TBL] [Abstract][Full Text] [Related]
7. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
[TBL] [Abstract][Full Text] [Related]
8. [Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature].
Junca A; Frouin E; Irani J; Fromont G; Levillain P
Ann Pathol; 2015 Dec; 35(6):496-501. PubMed ID: 26597142
[TBL] [Abstract][Full Text] [Related]
9. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
11. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
Goodin S; Medina P; Capanna T; Shih WJ; Abraham S; Winnie J; Doyle-Lindrud S; Todd M; DiPaola RS
J Clin Oncol; 2005 May; 23(15):3352-7. PubMed ID: 15738531
[TBL] [Abstract][Full Text] [Related]
12. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A
Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
[TBL] [Abstract][Full Text] [Related]
14. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
15. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
16. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Beltran H; Wyatt AW; Chedgy EC; Donoghue A; Annala M; Warner EW; Beja K; Sigouros M; Mo F; Fazli L; Collins CC; Eastham J; Morris M; Taplin ME; Sboner A; Halabi S; Gleave ME
Clin Cancer Res; 2017 Nov; 23(22):6802-6811. PubMed ID: 28842510
[No Abstract] [Full Text] [Related]
17. Hormone therapy in advanced prostate cancer.
Forster TH; Stoffel F; Gasser TC
Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
[No Abstract] [Full Text] [Related]
18. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
19. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W; Ackler J; Tijani L; Leighton J
Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
